Buckingham Upgrades Cephalon (CEPH) to Accumulate
More News related to CEPH
- Cephalon Added to S&P 500 Today
- Morning Movers 11/12: Best Buy (BBY) Sinks On Lower Guidance; GM (GM) Up On Bailout Hope
- Standard & Poor's Announces Changes to U.S. Indices
- After-Hours Movers 11/11: Intrepid Potash (IPI) Down On Results, Cephalon (CEPH) Up on S&P 500 Add
- S&P Announces Changes to US Indices: CEPH for GGP, ME for CEPH
More News related to Upgrades
- Merrill Smacks Down the REIT Space: Downgrades 29 Stocks, Upgrades 2
- Solars Rise as Merrill Downgrades First Solar (FSLR), SunPower (SPWRA)
- Merrill Lynch Downgrades Autodesk (ADSK) to Underperform
- Friedman Billings Downgrades Goodrich (GR) to Market Perform
- Friedman Billings Downgrades Spirit AeroSystems (SPR) to Market Perform
Buckingham Research upgrades Cephalon (Nasdaq: CEPH) from Neutral to Accumulate.
Cephalon, Inc., a biopharmaceutical company, engages in the discovery, development, and marketing of products to treat human diseases in the United States and internationally.
Related Categories
UpgradesStocks Mentioned
-0.46Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
